PE20100366A1 - Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion - Google Patents

Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion

Info

Publication number
PE20100366A1
PE20100366A1 PE2009001196A PE2009001196A PE20100366A1 PE 20100366 A1 PE20100366 A1 PE 20100366A1 PE 2009001196 A PE2009001196 A PE 2009001196A PE 2009001196 A PE2009001196 A PE 2009001196A PE 20100366 A1 PE20100366 A1 PE 20100366A1
Authority
PE
Peru
Prior art keywords
antigens
per
cough
vaccine
whoous
Prior art date
Application number
PE2009001196A
Other languages
English (en)
Inventor
Rajesh Jain
Sukhjeet Singh
Lavit Jambu
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of PE20100366A1 publication Critical patent/PE20100366A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA VACUNA DE COMBINACION LIQUIDA QUE CONTIENE: A) ANTIGENOS DE LA DIFTERIA (D) EN UNA CANTIDAD DE 1 A 40 Lf; B) ANTIGENOS DEL TETANOS (T) EN UNA CANTIDAD DE 1 A 25 Lf; C) ANTIGENOS DE LA TOS FERINA ACELULAR (aP) TALES COMO i) EL TOXOIDE DE LA TOS FERINA (PT) EN UNA CANTIDAD DE 1 A 40 ug POR 0.5 ML, ii) HEMAGLUTININA FILAMENTOSA (FHA) EN UNA CANTIDAD DE 1 A 40 ug POR 0.5 ML, iii) PERTACTINA (PRN) EN UNA CANTIDAD DE 1 A 15 ug POR 0.5 ML, Y iv) LAS PROTEINAS FIMBRIALES (FIM 1, 2 Y 3), DONDE LOS ANTIGENOS D, T Y aP SON ADSORBIDOS EN FOSFATO DE ALUMINIO; D) ANTIGENOS DE HAEMOPHILUS INFLUENZAE (Hib) EN UNA CANTIDAD DE 1 A 20 ug POR 0.5 ML, DONDE EL ANTIGENO Hib NO SE ADSORBE A NINGUN ADYUVANTE; E) ANTIGENOS DE HEPATITIS (Hep) EN UNA CANTIDAD DE 1 A 25 ug POR 0.5 ML, DONDE EL ANTIGENO Hep ES ADSORBIDO EN HIDROXIDO DE ALUMINIO; F) ANTIGENOS DEL POLIOVIRUS O VACUNA ANTIPOLIOMIELITICA INACTIVADA (IPV) TALES COMO CEPAS MAHONEY TIPO 1, MEF TIPO 2 Y SAUKETT TIPO 3, QUE SE ENCUENTRAN EN UNA CANTIDAD DE 1 A 50 DU, 1 A 15 DU Y 1 a 50 DU REPECTIVAMENTE, POR 0.5 ML; Y G) UN PRESERVANTE TAL COMO 2-FENOXIETANOL (2-POE). SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHA VACUNA ES UTIL PARA LA PROTECCION CONTRA ENFERMEDADES TALES COMO DIFTERIA, TETANOS, TOS FERINA ACELULAR
PE2009001196A 2008-10-24 2009-10-22 Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion PE20100366A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2438DE2008 2008-10-24

Publications (1)

Publication Number Publication Date
PE20100366A1 true PE20100366A1 (es) 2010-05-21

Family

ID=42119003

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009001196A PE20100366A1 (es) 2008-10-24 2009-10-22 Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion

Country Status (14)

Country Link
US (1) US8551451B2 (es)
EP (2) EP2529749A1 (es)
JP (1) JP2012506421A (es)
CN (1) CN102196818A (es)
AP (1) AP2011005701A0 (es)
AR (1) AR073959A1 (es)
BR (1) BRPI0920630A2 (es)
CA (1) CA2741396A1 (es)
CL (1) CL2011000914A1 (es)
CO (1) CO6430434A2 (es)
MA (1) MA32819B1 (es)
PE (1) PE20100366A1 (es)
RU (2) RU2526214C2 (es)
WO (1) WO2010046935A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007293672B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
RU2705163C2 (ru) * 2011-01-05 2019-11-05 Бхарат Байотек Интернэшнл Лимитед Комбинированная семивалентная вакцина
FR2985663B1 (fr) * 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
FR2992656B1 (fr) * 2012-07-02 2016-10-07 Sanofi Pasteur Procede de production d'antigenes haemophilus influenzae type b
AU2013304048B2 (en) * 2012-08-17 2018-03-01 Intervet International B.V. An immunogenic composition of killed Leptospira bacteria
NZ630868A (en) * 2013-03-08 2017-02-24 Janssen Vaccines & Prevention Bv Acellular pertussis vaccine
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP6564367B2 (ja) * 2013-08-05 2019-08-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 併用免疫原性組成物
CN105861535B (zh) * 2015-01-20 2019-10-25 中国人民解放军军事医学科学院生物工程研究所 伤寒糖蛋白的生物制备方法及其应用
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
JP7404226B2 (ja) * 2017-07-18 2023-12-25 セラム インスティテュート オブ インディア プライベート リミティド 向上した安定性、高度の免疫原性、及び減少した反応源性を有する免疫原性組成物、並びにその調製プロセス
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
CN110917344B (zh) * 2019-12-26 2022-11-04 北京科兴中维生物技术有限公司 一种液体疫苗组合物及其应用
CN111053898B (zh) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 一种疫苗组合物及其应用
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
WO2022251434A1 (en) * 2021-05-26 2022-12-01 Emory University Jak inhibitors for managing conditions in patients with down's syndrome or other trisomy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334297D1 (de) * 1992-05-23 2009-11-12 Glaxosmithkline Biolog Sa Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
SK283565B6 (sk) * 1996-07-02 2003-09-11 Connaught Laboratories Limited Multivalentná imunogénna kompozícia a jej použitie
DK1028750T3 (da) 1997-09-15 2006-05-22 Sanofi Pasteur Msd Fremgangsmåde til fremstilling af multivalente vacciner
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
WO2007026249A2 (en) * 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup c meningococcus
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture

Also Published As

Publication number Publication date
JP2012506421A (ja) 2012-03-15
MA32819B1 (fr) 2011-11-01
EP2362781A1 (en) 2011-09-07
BRPI0920630A2 (pt) 2016-01-12
CA2741396A1 (en) 2010-04-29
EP2362781A4 (en) 2012-12-05
RU2013101418A (ru) 2014-07-20
AR073959A1 (es) 2010-12-15
US8551451B2 (en) 2013-10-08
RU2011120308A (ru) 2012-11-27
AP2011005701A0 (en) 2011-06-30
US20110206726A1 (en) 2011-08-25
RU2634393C2 (ru) 2017-10-26
RU2526214C2 (ru) 2014-08-20
CL2011000914A1 (es) 2012-01-20
WO2010046935A1 (en) 2010-04-29
CN102196818A (zh) 2011-09-21
EP2529749A1 (en) 2012-12-05
CO6430434A2 (es) 2012-04-30

Similar Documents

Publication Publication Date Title
PE20100366A1 (es) Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es) Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
NZ592977A (en) IgE CH3 PEPTIDE VACCINE
HRP20110431T1 (hr) Kombinirano cjepivo od inaktiviranog poliovirusa
WO2008112344A3 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
AR053711A1 (es) Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion
UY37811A (es) Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
JP2012506421A5 (es)
PH12015501875A1 (en) Acellular pertussis vaccine
WO2012093406A3 (en) A combination heptavalent vaccine
PE20211648A1 (es) Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma
AR092896A1 (es) Composiciones inmunogenicas
PH12019500404A1 (en) Multivalent vaccine composition
WO2008097267A3 (en) Vaccines against vesicular stomatitis
AR117191A1 (es) Composiciones inmunogénicas
AR067471A1 (es) Un componente de vacuna anti- pertussis y procedimiento simplificado para obtener pertactina ( prn ) de bordetella pertussis
WO2017116177A3 (ko) 약독화된 돼지열병 바이러스 생마커백신주 및 이를 이용한 경구투여용 백신 조성물
AR089737A1 (es) Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse sobre el oxi-hidroxido de aluminio
GB201015223D0 (en) Vaccines
BR112012004703A2 (pt) regime de imunização inicial de reforço heterólogo contra o vírus da língua azul.
AR118407A1 (es) Composición de vacuna multivalente
WO2010023452A3 (en) Nematode vaccine
WO2007014179A3 (en) Method for controlling immunodominance
Verstraeten Rebuttal Letter to the Letter to the Editor to" Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines" by T. Verstraeten et al

Legal Events

Date Code Title Description
FA Abandonment or withdrawal